Immunotherapy with anti-CD20 compounds

被引：15
作者：
von Schilling, C [1 ]
机构：
[1] Tech Univ Munich, Klinikum Rechts Isar, Med Klin 3, D-81675 Munich, Germany
来源：
SEMINARS IN CANCER BIOLOGY | 2003年 / 13卷 / 03期
关键词：
B-cell lymphoma; CD20; clinical trials; monoclonal antibody;
D O I：
10.1016/S1044-579X(03)00018-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The B-cell surface antigen CD20 is currently the prime target for near-selective treatment of mature B-cell malignancies and a range of reactive B-cell associated disorders (including virus-associated lymphoproliferation or autoimmune conditions). CD20 is strongly and homogeneously expressed on the majority of mature B-cell neoplasms except chronic lymphocytic leukaemia cells, and on all mature reactive B-cells. This review will summarise the modes of action of various reagents targeting CD20. Treatment results following their use in single and combination therapy for B-cell disorders are reviewed. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：211 / 222
页数：12
相关论文
共 184 条
[81]  
Johnson TA, 2000, INT J CANCER, V85, P104, DOI 10.1002/(SICI)1097-0215(20000101)85:1<104::AID-IJC19>3.0.CO
[82]  
2-G
[83]   Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma:: updated results and long-term follow-up of the University of Michigan experience [J].
Kaminski, MS ;
Estes, J ;
Zasadny, KR ;
Francis, IR ;
Ross, CW ;
Tuck, M ;
Regan, D ;
Fisher, S ;
Gutierrez, J ;
Kroll, S ;
Stagg, R ;
Tidmarsh, G ;
Wahl, RL .
BLOOD, 2000, 96 (04) :1259-1266
[84]   Iodine-131 - Anti-B1 radioimmunotherapy for B-cell lymphoma [J].
Kaminski, MS ;
Zasadny, KR ;
Francis, IR ;
Fenner, MC ;
Ross, CW ;
Milik, AW ;
Estes, J ;
Tuck, M ;
Regan, D ;
Fisher, S ;
Glenn, SD ;
Wahl, RL .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) :1974-1981
[85]   RADIOIMMUNOTHERAPY OF B-CELL LYMPHOMA WITH [I-131] ANTI-B1 (ANTI-CD20) ANTIBODY [J].
KAMINSKI, MS ;
ZASADNY, KR ;
FRANCIS, IR ;
MILIK, AW ;
ROSS, CW ;
MOON, SD ;
CRAWFORD, SM ;
BURGESS, JM ;
PETRY, NA ;
BUTCHKO, GM ;
GLENN, SD ;
WAHL, RL .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (07) :459-465
[86]   Activation of the calcium-permeable cation channel CD20 by alpha subunits of the G(i) protein [J].
Kanzaki, M ;
Lindorfer, MA ;
Garrison, JC ;
Kojima, I .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (23) :14733-14739
[87]   EXPRESSION OF CALCIUM-PERMEABLE CATION CHANNEL CD20 ACCELERATES PROGRESSION THROUGH THE G(1) PHASE IN BALB/C 3T3 CELLS [J].
KANZAKI, M ;
SHIBATA, H ;
MOGAMI, H ;
KOJIMA, I .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (22) :13099-13104
[88]   MOLECULAR MECHANISMS REGULATING CD19, CD20 AND CD22 GENE-EXPRESSION [J].
KEHRL, JH ;
RIVA, A ;
WILSON, GL ;
THEVENIN, C .
IMMUNOLOGY TODAY, 1994, 15 (09) :432-436
[89]   An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab [J].
Kennedy, AD ;
Solga, MD ;
Schuman, TA ;
Chi, AW ;
Lindorfer, MA ;
Sutherland, WM ;
Foley, PL ;
Taylor, RP .
BLOOD, 2003, 101 (03) :1071-1079
[90]   Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review [J].
Kennedy, GA ;
Tey, SK ;
Cobcroft, R ;
Marlton, P ;
Cull, G ;
Grimmett, K ;
Thomson, D ;
Gill, D .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (02) :412-416
45678910111213